Literature DB >> 19217304

5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors.

Rosaria Ottanà1, Rosanna Maccari, Rosella Ciurleo, Paolo Paoli, Michela Jacomelli, Giampaolo Manao, Guido Camici, Christian Laggner, Thierry Langer.   

Abstract

As part of a project aimed at identifying effective low molecular weight nonphosphorus monoanionic inhibitors of PTPs, we have synthesized 4-[(5-arylidene-4-oxo-2-phenyliminothiazolidin-3-yl)methyl]benzoic acids (4) and evaluated their inhibitory activity against human PTP1B and LMW-PTP enzymes. The introduction of a 2-phenylimino moiety onto the 4-thiazolidinone ring was designed to enhance the inhibitor/enzyme affinity by means of further favourable interactions with residues of the active site and the surrounding loops. Some of the compounds (4a-d, f) showed interesting inhibition levels in the low micromolar range. The 5-arylidene moiety of acids 4 proved to markedly influence the potency of these inhibitors. Molecular modeling experiments inside the binding sites of both enzymes were performed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19217304     DOI: 10.1016/j.bmc.2009.01.044

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

Review 1.  Current therapies and emerging drugs in the pipeline for type 2 diabetes.

Authors:  Quang T Nguyen; Karmella T Thomas; Katie B Lyons; Loida D Nguyen; Raymond A Plodkowski
Journal:  Am Health Drug Benefits       Date:  2011-09

Review 2.  The role of protein tyrosine phosphatase 1B (PTP1B) in the pathogenesis of type 2 diabetes mellitus and its complications.

Authors:  Maryam Teimouri; Hossein Hosseini; Zahra ArabSadeghabadi; Reyhaneh Babaei-Khorzoughi; Sattar Gorgani-Firuzjaee; Reza Meshkani
Journal:  J Physiol Biochem       Date:  2022-01-06       Impact factor: 4.158

Review 3.  Human Protein Tyrosine Phosphatase 1B (PTP1B): From Structure to Clinical Inhibitor Perspectives.

Authors:  Rongxing Liu; Cécile Mathieu; Jérémy Berthelet; Wenchao Zhang; Jean-Marie Dupret; Fernando Rodrigues Lima
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

4.  Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase.

Authors:  Stephanie M Stanford; Alexander E Aleshin; Vida Zhang; Robert J Ardecky; Michael P Hedrick; Jiwen Zou; Santhi R Ganji; Matthew R Bliss; Fusayo Yamamoto; Andrey A Bobkov; Janna Kiselar; Yingge Liu; Gregory W Cadwell; Shilpi Khare; Jinghua Yu; Antonio Barquilla; Thomas D Y Chung; Tomas Mustelin; Simon Schenk; Laurie A Bankston; Robert C Liddington; Anthony B Pinkerton; Nunzio Bottini
Journal:  Nat Chem Biol       Date:  2017-03-27       Impact factor: 15.040

5.  Targeting LMW-PTP to sensitize melanoma cancer cells toward chemo- and radiotherapy.

Authors:  Giulia Lori; Paolo Paoli; Anna Caselli; Paolo Cirri; Riccardo Marzocchini; Monica Mangoni; Cinzia Talamonti; Lorenzo Livi; Giovanni Raugei
Journal:  Cancer Med       Date:  2018-03-24       Impact factor: 4.452

6.  2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.

Authors:  Ilkay Küçükgüzel; Gökhan Satılmış; K R Gurukumar; Amartya Basu; Esra Tatar; Daniel B Nichols; Tanaji T Talele; Neerja Kaushik-Basu
Journal:  Eur J Med Chem       Date:  2013-09-12       Impact factor: 6.514

Review 7.  Thiazolidinediones: An In-Depth Study of Their Synthesis and Application to Medicinal Chemistry in the Treatment of Diabetes Mellitus.

Authors:  Nathan Long; Adam Le Gresley; Stephen P Wren
Journal:  ChemMedChem       Date:  2021-05-04       Impact factor: 3.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.